Key facts
- It has raised $300K; the latest was Early Stage VC ($300K) in Oct 2025.
- Notable investors include Iker Marcaide, Zubi Labs.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for TeraDx
- ·The full record, as it builds
Funding rounds
No funding rounds for TeraDx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TeraDx
Developer of cancer diagnostic technology designed for the early detection of head and neck cancer. The company's technology integrates a microbiome process that offers saliva sample-based assessments, qPCR analysis, automated interpretation, and diagnostic reporting, enabling healthcare practitioners and individual patients to manage routine screenings, interpret results through secure portals, and integrate diagnostic insights into broader health management workflows.
- Sector
- Healthcare
- HQ
- Valencia, Spain
- Founded
- 2025
- Employees
- 2
- Website
- teradx.com/
- Ownership
- Privately Held (backing)
TeraDx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TeraDx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TeraDx in its N-PORT filings yet. We sweep new filings monthly.